Myriad Genetics (MYGN) Rises on Q2 Results

Myriad Genetics, Inc. (NASDAQ: MYGN) rose 10.8% to $17.06 after the company posted upbeat Q2 results and narrowed its FY17 adjusted earnings outlook. Share volume was 3.2 million, nearly tripling its all-day average